TL;DR
- •Stimulant "comedown" or "crash" is the cluster of symptoms that appears as the medication wears off — fatigue, irritability, dysphoric mood, increased appetite, and rebound of the original ADHD symptoms (often worse than baseline for a few hours).
- •Affects a meaningful fraction of ADHD patients on stimulants per recent pharmacovigilance data — among the most-reported quality-of-life issues with stimulant treatment.
- •Mechanism: stimulants rapidly raise dopamine and norepinephrine, then the brain compensates by downregulating, and the wearing-off period produces a relative deficit before normal homeostasis returns. Short-acting formulations produce more pronounced crashes.
- •Management ladder: switch to longer-acting formulations, add a small afternoon "booster" dose, address sleep and nutrition (crashes are worse on poor sleep and skipped meals), or add a non-stimulant ADHD medication (atomoxetine, guanfacine, viloxazine).
- •For patients whose ADHD is comorbid with depression and whose stimulant crashes worsen mood substantially, ketamine's NMDA/glutamate mechanism can stabilize the underlying mood condition independent of the dopaminergic stimulant cycle.
- •Lifestyle factors matter substantially — adequate sleep, regular meals (especially protein at lunch), aerobic exercise, and hydration reduce crash severity. Skipping meals while on stimulants is the most common preventable cause of severe crashes.
Medications most associated with this
What this is
Adderall comedown is the cluster of symptoms that appears in the hours when the stimulant is wearing off — typically late afternoon for short-acting formulations and early evening for XR or Vyvanse. Core features: deep fatigue (sometimes feeling more tired than before the dose), irritability with a short fuse, mood drop ranging from mild dysphoria to depression-like symptoms, increased and sometimes ravenous appetite, headache, and rebound ADHD symptoms (distractibility, restlessness) often worse than baseline. The combination can be deeply uncomfortable and is one of the most-reported reasons patients reduce or discontinue stimulant treatment.
Why it happens
Stimulants rapidly increase dopamine and norepinephrine release and inhibit reuptake — producing the therapeutic ADHD effect. The brain compensates by reducing dopamine receptor sensitivity and norepinephrine system tone. When the medication wears off, dopamine and norepinephrine signaling drops below the new, lower baseline before homeostasis re-equilibrates. The result is a temporary deficit in the very systems the medication was enhancing. Recent ADHD pharmacovigilance data confirms stimulant withdrawal/crash as among the most-reported adverse events. The phenomenon is dose-dependent (higher doses produce bigger crashes) and formulation-dependent (immediate-release crashes are sharper than extended-release).
Typical timeline
Crash typically appears 2-4 hours before the next dose would be due (for short-acting formulations) or in the evening hours (for XR/Vyvanse). Lasts 1-4 hours. Worst in the days/weeks after starting or increasing the dose, often attenuating as the body adapts. Some patients have persistent severe crashes that don't adapt. Crashes are worse on poor sleep, skipped meals, and during stressful periods. Tolerance develops over months — sometimes producing escalating dose needs alongside accumulating crash severity.
Management options
Discuss with your prescriber before adjusting any medication. These are options to bring up in conversation.
Switch to a longer-acting formulation
Adderall XR, Vyvanse (lisdexamfetamine), and Concerta (methylphenidate ER) produce smoother offset curves than immediate-release formulations. Crashes typically more gradual and less pronounced. Often the first intervention.
Add a small afternoon booster dose
A small immediate-release dose (5-10mg Adderall, 5-10mg methylphenidate) in the early afternoon can prevent the steep crash from the morning XR. Standard clinical practice for patients with afternoon crash on XR alone. Caution: late doses can disrupt sleep.
Optimize sleep, nutrition, and hydration
Crashes are substantially worse on poor sleep and skipped meals. Stimulants suppress appetite at peak effect; many patients don't eat properly during the day and then crash hard. A planned protein-rich lunch is one of the most-impactful interventions. Adequate sleep (7-9 hours) is essential.
Add a non-stimulant ADHD medication
Atomoxetine (Strattera), guanfacine ER, clonidine ER, and viloxazine (Qelbree) work through non-stimulant mechanisms and don't produce crashes. Can be used alongside stimulants to provide baseline coverage, or as monotherapy for patients who can't tolerate stimulant crashes.
Address comorbid mood or anxiety
Crashes often unmask or amplify underlying mood/anxiety symptoms. If crashes are particularly severe, screening for and treating comorbid depression or anxiety often substantially reduces crash impact.
Mechanism switch to ketamine for comorbid depression
For patients with ADHD plus depression where stimulant crashes substantially worsen mood, ketamine's NMDA/glutamate mechanism stabilizes the mood condition independent of the dopaminergic stimulant cycle. The combination of stimulant for ADHD plus ketamine for depression is well-tolerated and clinically coherent.
Where ketamine fits
ADHD and depression frequently co-occur, and the cycle of stimulant crash producing mood drop can be one of the most destabilizing patterns in dually-diagnosed patients. Ketamine's NMDA/glutamate mechanism is independent of the dopaminergic stimulant cycle — so it can stabilize mood without interfering with ADHD treatment. Many patients with ADHD plus treatment-resistant depression find that adding ketamine to their stimulant regimen produces substantial improvement in both the depression and the crash-related mood instability, without requiring stimulant discontinuation.
Check eligibility for ketamine therapy5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
Why do I crash so hard on Adderall?
Several factors: short-acting formulations (more abrupt offset), high doses (bigger compensation by the brain, bigger crash), poor sleep, skipped meals (especially low-protein lunches), and dehydration. Stress and life-load amplify everything. The combination of "stimulant + skipped breakfast + late lunch + dehydration + bad sleep" produces a much worse crash than any single factor alone.
Will switching from Adderall to Vyvanse help?
Often yes. Vyvanse has a smoother release curve and longer duration of action than immediate-release Adderall, producing a more gradual offset and milder crash. Vyvanse is one of the most common switch targets for patients with significant Adderall crashes. Adderall XR is another option, though Vyvanse typically has the smoothest profile.
Should I take a second dose to prevent the crash?
For some patients, a small afternoon booster (5-10mg Adderall IR or methylphenidate) prevents the steep afternoon crash and is standard clinical practice. Caution: late doses (after 3-4pm) can disrupt sleep and create a worse cycle. Coordinate timing with your prescriber.
Is the crash dangerous?
Not physically — but it can be functionally significant. Severe crashes affect work performance, relationships, eating patterns, and sleep. For some patients, the mood-drop component can briefly approach depressive intensity. The cumulative impact warrants attention even though no single crash is medically dangerous.
Should I consider ketamine for ADHD?
Ketamine isn't a treatment for ADHD itself — stimulants and non-stimulant ADHD medications remain the standard of care. But for ADHD patients with comorbid treatment-resistant depression, ketamine treats the depression alongside the ongoing ADHD regimen. This is the relevant use case, not ketamine as a replacement for ADHD medications.
Don’t stop your medication on your own
Even mild side effects deserve a clinical conversation. Stopping or adjusting antidepressants without coordination with your prescriber can cause discontinuation syndrome, depression breakthrough, or both. Bring these options to your next appointment.
References
- Ebina T et al. 2026, PCN Rep. ADHD medications and drug withdrawal: pharmacovigilance study using FDA Adverse Event Reporting System — confirms stimulant comedown as among the most-reported ADHD medication adverse events. PMID 42021984
- Amiri D et al. 2026, Neuropsychiatr Dis Treat. Central stimulants in a stressed brain — evidence synthesis of benefits, burnout risk, and crash-related complications. PMID 41767616
- Kessler RC et al. 2006, American Journal of Psychiatry. Prevalence and correlates of adult ADHD in the United States — establishes the comorbidity burden of ADHD with depression and anxiety that complicates crash management. PMID 16585449
- Murrough JW et al. 2013, American Journal of Psychiatry. Ketamine RCT in treatment-resistant depression — relevant for the substantial subset of ADHD patients with comorbid treatment-resistant depression. PMID 23982301